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Abstract
Background: Increasing evidence has demonstrated that long non-coding RNAs (lncRNAs) play essential roles in
the occurrence and development of human cancers, including gastric cancer (GC). However, the functional and
clinical significance of lncRNAs are still poorly understood.
Methods: In this study, the expression of LncRNA HNF1A antisense RNA 1 (HNF1A-AS1) was first examined by
lncRNAs microarray analysis in 6 GC tissues, and was then further verified by real-time quantitative reverse
transcription PCR (qRT-PCR) both in 3 GC cell lines and 161 cases of GC tissues. We also evaluated the association
between HNF1A-AS1 expression and clinicopathological features of patients with GC.
Results: LncRNAs microarray analysis results exhibited that HNF1A-AS1 was downregulated in GCs tissues (mean
fold change 2.06, p < 0.05), which was further confirmed by qRT-PCR. The results from qRT-PCR showed that the
expression of HNF1A-AS1 was not only downregulated in three GC cell lines (AGS, BGC-823, and MKN-45) relative to
that in a normal gastric mucosal epithelial cell line (GES-1), but also decreased in GC tissues relative to that in
paired adjacent non-neoplastic tissues (low expression, 94 of 161; low expression rate, 58.38 %). Furthermore, low
HNF1A-AS1 expression was associated with tumor size/diameter (p = 0.005, multivariate analysis), levels of serum
carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), and RRM1 expression in tissue samples
(p = 0.028, p = 0.009, and p = 0.006, respectively).
Conclusions: Taken together, our data indicate that lncRNA HNF1A-AS1 may be a regulator of GC, and thus, it may
have potential as a novel biomarker and treatment target for this type of cancer.
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Background
Gastric cancer (GC) is one of the most common cancers
and can occur in any section of the human stomach.
These tumors are frequently malignant and have the
ability to invade perineural tissue [1]. Data from the lat-
est global annual survey have shown that there are
almost 1 million new cases and 740,000 deaths from this
cancer per year worldwide. The incidence of GC in
China is higher than that in most countries in the world,
with more than 400,000 new cases each year and ap-
proximately 300,000 deaths. Studies have shown that if
this illness can be diagnosed at an early stage, good
prognosis can be achieved through complete surgical re-
section of the primary tumor tissue [2]. Unfortunately,
patients with GC show few symptoms in the early stages
of disease and diagnosis is usually difficult. The 5-year
survival rate of GC at advanced stages remains poor and
is stubborn at approximately 30 % [3]. Cancer bio-
markers allow cancer to be diagnosed and can serve as
therapeutic targets, as well as can be used to explore the
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pathogenesis of disease; therefore, identification of can-
cer biomarkers would be of great value.
Long non-coding RNAs (lncRNAs) are non-coding
RNAs greater than 200 nucleotides [4]. These RNAs do
not encode proteins and are the main components of
the human transcriptome [5]. Emerging evidence indi-
cates that lncRNAs are important regulatory molecules
whose main functions are related to modulation of gene
expression networks [6]. Many of these networks are
closely associated with cancer development and progres-
sion [6–9]. Data from different groups have determined
that changes in expression of lncRNAs are related to the
pathogenesis of diverse human cancers. Recent findings
from Wang et al., Song et al., and Shao et al. have dem-
onstrated that changes in the expression profiles of
lncRNAs are linked to gastric cancer carcinogenesis and
progression and that lncRNAs could be used as early
biomarkers or as treatment targets for GC [10–12].
In order to identify the abnormal expression of tumor-
related LncRNAs and those LncRNAs with potential
values as biomarkers, in this study, the lncRNAs expres-
sion profile microarray analysis was performed in six GC
tissue and their paired adjacent non-neoplastic gastric
tissues. LncRNA HNF1A antisense RNA 1 (HNF1A-
AS1) was one of the LncRNAs that were identified to be
downregulated in GC tissues by the microarray analysis.
HNF1A-AS1, a single-exon gene at band 12q24.31 of
chromosome 12, is a bidirectional lncRNA of 2455 nu-
cleotides [13]. The transcriptional start site of this
lncRNA is very close to that of hepatic nuclear factor 1
alpha gene (HNF1A; HNF1A-AS1’s start site is approxi-
mately 5 kb downstream of HNF1A) [13]. To our know-
ledge, the expression of HNF1A-AS1 in GC tissues
remains unreported. Therefore, in this work, we deter-
mined the expression levels of HNF1A-AS1 in 3 GC cell
lines and in 161 cases of GC tissues and their paired ad-
jacent non-neoplastic gastric tissues. We also investi-
gated the potential association between the expression
of HNF1A-AS1 and clinicopathological features of pa-
tients with GC. Our data illustrate the potential of this
lncRNA as a novel biomarker and a treatment target for
GC.
Methods
Tissue samples and clinical data collection
One hundred and sixty-one fresh paired tissue samples
(GC tissue and non-neoplastic tissues collected 5 cm
from the cancer’s edge) were obtained from Fuzhou
General Hospital, Fujian, China, in 2014 and 2015. All of
the samples were obtained immediately after surgical
operation and preserved in RNAlater (Qiagen, Germany)
at −80 °C until use. Serum samples used for detection of
the serum tumor biomarkers and paraffin-embedded tissue
samples used for detection of the immunohistochemical
markers were also collected from the same patients. Every
tissue sample was histopathologically diagnosed and con-
firmed by at least two pathologists. The standards for
tumor-node-metastasis (TNM) stage and histological grade
were in accordance with the guidelines of the International
Union Against Cancer (UICC; 5th Ed) and the National
Comprehensive Cancer Network’s (NCCN) Clinical Prac-
tice Guidelines in Oncology (V.1.2011), respectively. None
of the patients received treatment prior to resection.
Ethics statement
Informed consent was obtained from all individual partici-
pants included in the study, and this study was approved
by the Ethics Committee of Fuzhou General Hospital.
LncRNAs microarray assay
The lncRNAs microarrays used in this study were the
Human LncRNAs Microarray V3.0 (Arraystar Inc., MD,
USA), which was composed of lncRNAs and mRNAs
from the human genome. lncRNAs microarray assay and
the data analysis were performed by KANGCHEN Bio-
tech (Shanghai, China) based on the instructions of the
manufacturer.
Cell culture
AGS, BGC-823, and MKN-45 GC cell lines and normal
human gastric epithelial cell line (GES-1) were obtained
from the American Type Culture Collection, Manassas,
VA, Shanghai Institute of Biochemistry and Cell Biology,
the Chinese Academy of Sciences in Shanghai, China,
Japanese Cancer Research Bank and Beijing Cancer
Institute (Beijing, China), respectively. The cells were
grown in F12, RP1640, or DMEM medium (Invitrogen,
Grand Island, NY, USA), all of which contained 10 % fetal
bovine serum, in an incubator at 37 °C with 5 % CO2.
Total RNA extraction and qRT-PCR
Total RNAs were isolated from both tissues and cultured
cells by using TRIzol reagent (Invitrogen). Reverse tran-
scription was then performed by using a Reverse Transcrip-
tion kit (Promega) in accordance with the instructions of
the manufacturer. Real-time quantitative reverse transcrip-
tion PCR (qRT-PCR) was carried out by using the SYBR
Green Mix kit (Promega, Madison, WI, USA) in a Step
One Real-time PCR System (ABI, Grand Island, NY, USA).
The primers for 18s and HNF1A-AS1 qPCR were as
follows: (forward) 5′-TCAAGAAATGGTGGCTAT-3′ and
(reverse) 5′-GCTCTGAGACTGGCTGAA-3′ for HNF1A-
AS1; (forward) 5′-AGAAACGGCTACCACATCCA-3′ and
(reverse) 5′-CACCAGACTTGCCCTCCA-3′ for 18s. The
conditions for PCR were as follows: stage 1, 95 °C for
10 min; stage 2, 40 cycles at 95 °C for 15 s, 57 °C for
1 min; stage 3 (dissociation stage), 95 °C for 15 s, 60 °C
for 15 s, 95 °C for 15 seconds. The recorded cycle
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threshold (Ct) values included both HNF1A-AS1 and
18 s; the latter served as a control. The expression level
of HNF1A-AS1 was obtained by using the ΔCt method.
Higher ΔCt values indicated lower HNF1A-AS1 expres-
sion. The results were obtained from three independent
experiments and expressed as the mean ± standard
deviation (SD).
Measurement of AFP, CA-125, CEA, and CA19-9 concentrations
in the serum of patients with GC
The concentrations of alpha-fetoprotein (AFP), carcinoem-
bryonic antigen (CEA), cancer antigen 125 (CA-125), and
carbohydrate antigen 19-9 (CA19-9) were detected in the
serum of all of 161 cases of this group patients by using the
Quantitative Kit for Tumor Marker (Protein Chip-
Chemiluminescence) (HealthDigit, Huzhou, China) with
the HD-2001A ChipReader System (HealthDigit). In this
study, the normal reference values for healthy individuals
were <20.0 ng/ml, <5.0 ng/ml, <35.0 U/ml and <35.0 U/ml
for AFP, CEA, CA-125, and CA19-9, respectively.
IHC
We used immunohistochemistry (IHC) in paraffin-
embedded sections to determine the expression of vascular
endothelial growth factor (VEGF), human epidermal
growth factor receptor 2 (C-erbB-2 or HER2), thymidylate
synthase (TS), breast cancer 1 (BRCA1), excision repair
cross-complementation group 1 (ERCC1), Ki67 antigen
(Ki67), and ribonucleotide reductase subunit M1 (RRM1),
synaptophysin (Syn), neuronal cell adhesion molecules
(CD56), and chromogranin A (CgA); 150 cases of the
paraffin-embedded tissue samples of this group patients
were available for the IHC assay. IHC was performed by
pathologists in accordance with the instructions of the
manufacturers. The antibodies and other reagents for IHC
used in this work were purchased from Maixin (Fujian,
China) and ZSGB-BIO (Beijing, China). With the exception
of Ki67, the intensity of staining was graded from 0 to 4,
with 0 being no staining; 1, less than 25 % of cells positive;
2, 25 to 50 % of cells positive; 3, 51 to 75 % of cells positive;
and 4, >76 % cells positive. For Ki67, the grades were dir-
ectly judged as the percent positive for Ki67 expression.
The slides were graded by at least two pathologists.
Statistical analysis
Statistical Program for Social Sciences (SPSS) 16.0 software
(SPSS, Chicago, IL, USA) and GraphPad Prism 5.0 (Graph-
Pad Software, LaJolla, CA, USA) were used for all statistical
analyses. One-way analysis of variance (ANOVA), the rank-
sum test, and the Student’s t test were main statistical
methods used in this work, the p < 0.05 was regarded as
statistically significant.
Results
LncRNAs microarray analysis exhibits that HNF1A-AS1
expression is downregulated in GCs tissues
As shown in Fig. 1, the results of lncRNAs expression pro-
file microarray analysis gotten from six GC tissues and
their paired adjacent non-neoplastic gastric tissues exhib-
ited that HNF1A-AS1 expression was downregulated in all
of the six GC tissues (mean fold change 2.06, p < 0.05),
which indicated that this lncRNA may have the potential
to be one of the tumor-related LncRNAs. Thus, we chose
it for further analysis.
Fig. 1 HNF1A-AS1 was downexpressed in six GC tissues identified by lncRNAs microarray analysis. 84C, 83C, 87C, 78C, 97C, and 90C indicated six GC tissues
(84, 83, 87, 78, 97, and 90 were the six cases of tissue number, C cancer); 83N, 87N, 90N, 78N, 97N, and 84N indicated the six corresponding paired adjacent
non-neoplastic gastric tissues (N non-neoplastic gastric tissues). Cluster analysis based on the microarray results exhibited that HNF1A-AS1 expression in GC
tissues was downregulated compared with that of paired non-neoplastic gastric tissues (mean fold change 2.06, p< 0.05)
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qRT-PCR verification further confirms that HNF1A-AS1
expression is downregulated in GC cell lines and tissues
We first investigated the expression of lncRNA HNF1A-
AS1 in three GC cell lines: AGS, BGC-823, and MKN-45.
By using qRT-PCR, we confirmed that the expression of
HNF1A-AS1 was significantly decreased in all three GC cell
lines relative to that in normal gastric epithelial cells
(GES-1 cells; AGS, p < 0.0001; BGC-823, p < 0.05; MKN-
45, p < 0.05; Fig. 2). We also examined HNF1A-AS1
expression in GC tissue samples and paired adjacent non-
neoplastic tissue samples. Our results showed that
HNF1A-AS1 was downregulated in 58.38 % (94/161) of
GC tissues relative to that in the non-neoplastic tissues
(p < 0.01, Fig. 3). Taken together, these data indicate that
HNF1A-AS1 is downregulated in human GC.
Association of HNF1A-AS1 expression with
clinicopathological features of patients with GC
To assess the clinical significance of HNF1A-AS1, we
analyzed the relationship between its expression and clini-
copathological features of patients with GC. As shown in
Tables 1 and 2, the univariate analysis exhibited that the ex-
pression of HNF1A-AS1 was associated with tumor size/
diameter (p = 0.002), invasion depth (T stages, p = 0.032),
lymphatic metastasis (N stages, p = 0.006), venous invasion
(p = 0.001), and perineural invasion (PNI, p = 0.014). How-
ever, after controlling affect factors including age, sex,
tumor location, tumor size/diameter, differentiation,
invasion (T stages), lymphatic metastasis (N stages), venous
invasion, and PNI, the multivariate analysis further con-
firmed that tumor size persisted to be significantly
correlated to HNF1A-AS1 expression (p = 0.005), which
meant that patients with tumor size ≥5 cm had lower levels
of HNF1A-AS1. These data suggest that HNF1A-AS1 may
play roles during cancer occurrence and progression and
may be a new biomarker of gastric cancer.
Association of HNF1A-AS1 expression with serum or
immunohistochemical markers of GC
HNF1A-AS1 expression in GC tissues was associated with
two serum markers of digestive tract tumors, CEA
(p = 0.028) and CA19-9 (p = 0.009), but there was no sig-
nificant association with other digestive tract cancer
serum marker AFP or with the epithelial tumor marker
CA125 (Table 1). The expression of HNF1A-AS1 in tumor
samples was also significantly correlated with one immu-
nohistochemical markers of cancer, RRM1 (p = 0.006), but
not with VEGF, C-erbB-2, TS, BRCA1, ERCC1, Ki67,
CD56, Syn, or CgA (Table 3).
Discussion
Several lines of evidence have demonstrated that
changes in expression of lncRNAs play important roles
in carcinogenesis and cancer development [14, 15] and
that altered expression of lncRNA is known to be
significantly associated with several clinicopathological
features of human tumors, such as lymph node
metastasis, TNM stage, distant metastasis, and the grade
of tissue differentiation. For example, decreased expres-
sion of gastric cancer-associated transcript 1 (GACAT1)
is significantly associated with metastasis, invasion, and
Fig. 2 Decreased expression of HNF1A-AS1 in GC cells relative to
that in normal gastric epithelial cells. qRT-PCR was used to compare
the expression of HNF1A-AS1 in BGC-823, MKN-45, and AGS GC cells
to that of non-neoplastic GES-1 cells. Data shown are from three
independent experiments and expressed as the mean ± SD.
Asterisks indicate values with a statistically significant difference
versus the value in GES-1 cells. *p< 0.05, ****p< 0.0001. GC gastric cancer,
qRT-PCR quantitative real-time PCR, SD standard deviation
Fig. 3 Expression of HNF1A-AS1 in neoplastic and non-neoplastic gastric
tissues. The expression of HNF1A-AS1 in GC tissues was compared to that
in adjacent non-neoplastic tissues (n = 161, **p < 0.01). T GC tissues,
N non-neoplastic tissues. Data shown are from three independent
experiments and expressed as the mean ± SD (ΔCt value). GC gastric
cancer, SD standard deviation
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tissue differentiation in patients with GC [16]. In
addition, elevated expression of homeobox (HOX) tran-
script antisense RNA (HOTAIR), a long intergenic non-
coding RNA, is associated with the grade of endometrial
carcinoma (EC), metastasis, depth of myometrial invasion,
and poorer overall survival [17]. Finally, low expression of
HMlincRNA717 in GC is associated with distal metastasis
and invasion of the venous and nervous systems [12]. All of
these findings are evidence of the important roles of
lncRNAs in carcinogenesis and of the potential value in
their clinical application.
In this study, we determined that the expression level of
HNF1A-AS1 in three gastric cancer cell lines was signifi-
cantly decreased relative to that in normal gastric epithelial
cells. More importantly, it was downregulated in 58.38 % of
gastric cancer tissue samples relative to that in adjacent
non-neoplastic tissues. The findings from Yang et al. show
that this lncRNA was upregulated in esophageal adenocar-
cinoma (EAC) [13]. Carcinogenesis and cancer progression
is a complex pathological process that is mediated by gene
expression networks. Cancer occurrence in different organs
or tissues may be regulated by differentially expressed levels
of the same genes or the same lncRNAs [18, 19]. This may
explain why HNF1A-AS1 exhibits divergent expression
profiles in different types of cancer cells. Further investiga-
tion may be necessary to reveal the precise molecular
mechanism for these differences.
Table 1 Association of HNF1A-AS1 expression (ΔCt) with
clinicopathological features of patients
Characteristics No. of case (%) Mean ± SD p value
Age (years) 0.119
≥60 82(50.9) 16.17 ± 2.90
<60 79(49.1) 15.47 ± 2.71
Gender 0.688
Male 123(76.4) 15.78 ± 2.88
Female 38(23.6) 15.99 ± 2.66
Tumor location 0.560
Sinuses ventriculi 57(35.4) 16.06 ± 3.13
Cardia 33(20.5) 15.87 ± 3.04
Corpora ventriculi 45(28.0) 15.92 ± 2.50
Others 26(16.1) 15.11 ± 2.36
Diameter(cm) 0.002
≥5 73(45.3) 16.59 ± 2.8
<5 88(54.7) 15.2 ± 2.70
Differentiation 0.396
Well 2(1.2) 16.15 ± 0.71
Moderate 34(21.1) 15.24 ± 2.66
Poor 125(77.7) 15.98 ± 2.87
Invasion 0.032
T1 13(8.1) 16.13 ± 1.95
T2 14(8.7) 14.09 ± 2.24
T3 16(9.9) 14.85 ± 3.71
T4 118(73.3) 16.13 ± 2.76
Lymphatic metastasis 0.006
N0 38(23.6) 14.74 ± 2.77
N1-3 123(76.4) 16.16 ± 2.76
Venous invasion 0.001
Absent 86(53.4) 15.14 ± 2.58
Present 75(46.6) 16.61 ± 2.90
Perineural invasion (PNI) 0.014
Absent 89(55.3) 15.34 ± 2.77
Present 72(44.7) 16.43 ± 2.79
CEA 0.028
Normal 130(80.7) 15.59 ± 2.74
High 31(19.3) 16.83 ± 2.97
CA19-9 0.009
Normal 140(87.0) 15.60 ± 2.70
High 21(13.0) 17.32 ± 3.22
Table 1 Association of HNF1A-AS1 expression (ΔCt) with
clinicopathological features of patients (Continued)
AFP 0.936
Normal 150(93.2) 15.82 ± 2.80
High 11(6.8) 15.89 ± 3.25
CA-125 0.494
Normal 154(95.7) 15.79 ± 2.84
High 7(4.3) 16.55 ± 2.33
Italicized values are significant at p < 0.05
Table 2 Comparison of the p values obtained from univariate
and multivariate analyses of the association of HNF1A-AS1
expression (ΔCt) with clinicopathological features of patients
Characteristics Univariate Multivariate
p value p value
Age (years) 0.119 0.197
Gender 0.688 0.174
Diameter (cm) 0.002 0.005
Differentiation 0.396 0.603
Invasion 0.032 0.580
Lymphatic metastasis 0.006 0.235
Venous invasion 0.001 0.057
Perineural invasion (PNI) 0.014 0.192
Tumor location 0.560 0.342
Italicized values are significant at p < 0.05
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It is well known that cancer invasion and metastasis
frequently occurs via three common pathways: lymph
node metastasis, travel through the vasculature, and
local seeding and growth. PNI is an additional means of
invasion that is usually correlated with local recurrence.
Because local recurrence is closely associated with poor
prognosis, identifying patients at high risk of PNI has
great clinical significance.
The prognosis and survival of patients with GC may also
be affected by the size of the tumor, which is related to its
time of growth. Smaller tumors exhibit less infringement
into the stomach than do larger tumors. Moreover, in-
creased depth of invasion by larger tumors increases the
likelihood that the lymphatic system will be breached. In-
creasing lymph node metastasis allows the cancer to grow
more easily and results in poor prognosis.
Both CEA and CA19-9 are well-known tumor markers
that are usually upregulated in serum or tissue samples
from patients with early or primary malignant tumors of
the digestive tract. RRM1 is one of the three known hu-
man ribonucleotide reductase with the functions of
regulating the cancer cell proliferation via mediating
DNA synthesis and repair, and detection of the expres-
sion of RRM1 in GC tissues by IHC has been identified
to have prognostic significance in patients with GC [20].
Conclusions
In summary, we analyzed the association of the expression
level of HNF1A-AS1 with the clinicopathological features
of patients with GC. Our results showed that the expres-
sion of HNF1A-AS1 was significantly downregulated in
both GC tissues and cell lines. Moreover, decreased ex-
pression was associated with tumor size/diameter and
levels of serum CEA, CA19-9, and tissue RRM1. These
findings indicate that HNF1A-AS1 may be involved in
Table 3 Association of HNF1A-AS1 expression (ΔCt) with
immunohisochemical features of GC tissue
Characteristics No. of case (%) Mean ± SD p value
VEGF 0.809
0 15 (10.0) 15.27 ± 3.69
1 22 (14.7) 15.57 ± 2.92
2 33 (22.0) 15.83 ± 2.72
3 59 (39.3) 15.94 ± 2.54
4 21 (14.0) 16.39 ± 3.32
C-erbB-2 0.312
0 129 (86.0) 15.70 ± 2.84
1 5 (3.3) 16.37 ± 2.96
2 4 (2.7) 15.77 ± 1.01
3 12 (8.0) 17.30 ± 3.21
TS 0.543
0 22 (14.7) 16.41 ± 2.45
1 53 (35.3) 15.99 ± 2.97
2 52 (34.7) 15.33 ± 2.73
3 21 (14.0) 16.25 ± 3.34
4 2 (1.3) 15.92 ± 1.82
BRCA1 0.893
0 10 (6.7) 16.59 ± 1.83
1 31 (20.7) 16.07 ± 2.91
2 73 (48.6) 15.78 ± 2.57
3 34 (22.7) 15.61 ± 3.57
4 2 (1.3) 15.77 ± 5.01
ERCC1 0.585
0 19 (12.7) 15.81 ± 2.39
1 22 (14.7) 16.51 ± 3.61
2 44 (29.3) 15.96 ± 2.85
3 41 (27.3) 15.85 ± 3.05
4 24 (16.0) 15.11 ± 2.02
RRM1 0.006
0 81 (54.0) 15.79 ± 2.41
1 10 (6.7) 13.27 ± 4.11
2 17 (11.3) 15.51 ± 3.08
3 35 (23.3) 16.98 ± 2.93
4 7 (4.7) 15.48 ± 2.67
Ki67 0.328
1 14 (9.3) 16.54 ± 1.67
2 35 (23.3) 16.44 ± 2.79
3 57 (38.0) 15.48 ± 2.97
4 44 (29.4) 15.66 ± 3.02
Syn 0.463
0 128 (85.3) 15.99 ± 2.95
Table 3 Association of HNF1A-AS1 expression (ΔCt) with
immunohisochemical features of GC tissue (Continued)
1 16 (10.7) 15.15 ± 2.17
2 3 (2.0) 13.98 ± 0.87
3 3 (2.0) 15.59 ± 3.06
CD56 0.364
0 137 (91.4) 15.94 ± 2.86
1 9 (6.0) 15.66 ± 3.09
2 2 (1.3) 12.72 ± 0.84
3 2 (1.3) 14.22 ± 0.97
CgA 0.980
0 141 (94.0) 15.87 ± 2.91
1 7 (4.7) 15.69 ± 1.83
2 2 (1.3) 15.63 ± 3.26
Italicized values are significant at p < 0.05
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suppression of gastric cancer occurrence and development
and that it has the potential to serve as a novel treatment
target and biomarker for the evaluation of disease severity
in patients with GC. Because the sample size of this study
was relatively small, further verification may be necessary
to confirm HNF1A-AS1’s true clinical value.
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